INGENIA Therapeutics is developing durable best-in-class therapeutic antibodies, restoring dysfunctional microvessels into their healthy state in multiple ophthalmic and systemic diseases. The company's unique science is based on its proprietary platform for the discovery and development of novel antibodies that target specific proteins involved in the regulation of microvascular function. INGENIA Therapeutics' lead product candidate is a monoclonal antibody that targets a key protein involved in the development of diabetic retinopathy, a leading cause of blindness.

Ingenia Therapeutics

Short description:

Drug notes:

Long description:

Jobs: